Coronary and Structural Heart Disease Interventions During COVID-19 Pandemic: A Road Map for Clinicians and Health Care Delivery Systems.

BACKGROUND: Because of the COVID-19 pandemic, cath labs have had to modify their workflow for elective and urgent patients. METHODS: We surveyed 16 physicians across 3 hospitals in our healthcare system to address COVID-19 related concerns in the management of interventional and structural heart disease patients, and to formulate system wide criteria for deferring cases till after the pandemic. RESULTS: Our survey yielded common concerns centered on the need to protect patients, cath lab staff and physicians from unnecessary exposure to COVID-19; for COVID-19 testing prior to arrival to the cath lab; for clear communication between the referring physician and the interventionalist; but there was initial uncertainty among physicians regarding the optimal management of ST elevation myocardial infarction (STEMI; percutaneous coronary intervention versus thrombolytics). Patients with stable angina and hemodynamically stable acute coronary syndromes were deemed suitable for initial medical management, except when they had large ischemic burden. Most transcatheter aortic valve implantations (TAVI) were felt appropriate for postponement except in symptomatic patients with aortic valve area <0.5 cm2 or recent hospitalization for heart failure (HF). Most percutaneous mitral valve repair (pMVR) procedures were felt appropriate for postponement except in patients with HF. All left atrial appendage closure (LAAC) and patent foramen ovale (PFO)/atrial septal defect (ASD) closure procedures were felt appropriate for postponement. CONCLUSION: Our survey of an experienced team of clinicians yielded concise guidelines to direct the management of CAD and structural heart disease patients during the initial phases of the COVID-19 pandemic.

Comparison of transfusion requirements for conventional and miniaturized extracorporeal circuits.

OBJECTIVE: Hemodilution is a well-recognized phenomenon of cardiopulmonary bypass (CPB). The degree of hemodilution has attendant risks. As the degree of hemodilution increases, red blood cell transfusions may be necessary, and the risks of blood transfusions are becoming very well recognized. Blood-conservation programs are being developed worldwide to establish strategies to reduce transfusions. Miniaturized extracorporeal circuits (MECs) are associated with less hemodilution than conventional CPB circuits. The use of MECs can be expected to be associated with fewer red blood cell transfusions. METHODS: The first 250 patients who underwent coronary artery bypass grafting, aortic valve replacement, or both with the use of a MEC were compared with 200 consecutive patients who had similar comorbidities and types of surgery but underwent their operations on a conventional bypass circuit. These surgeries were completed between April 2004 and September 2005 under the care of the same surgical team. The minimum acceptable hematocrit on bypass was 22%. Intra- and postoperative transfusion rates were measured and compared. RESULTS: For conventional bypass, the intraoperative transfusion rate was 36.5%, whereas the rate for the MEC was 23.3%. The postoperative transfusion rate was 55% for operations performed with conventional bypass and 26% for the MEC. The overall in-hospital transfusion rate for conventional bypass was 63% and 36% for the MEC. CONCLUSIONS: The data indicate that use of MECs leads to a lower transfusion rate than in surgeries in which conventional CPB is used.

Long-term results of surgical lead implantation for biventricular pacemakers in cardiomyopathy patients.

Patients with congestive heart failure commonly display dysynchronous contraction patterns and weakened cardiac performance. Cardiac resynchronization therapy from biventricular pacing has been proven effective using coronary sinus cannulation or a less common surgical approach. In this study, the beneficial effects of implanting biventricular leads using the surgical approach for New York Heart Association functional class 3 or 4 patients (mean, 3.4 +/- 0.5) were evaluated in 19 patients (17 male, 2 female). Pacing thresholds after 2 years were deemed favorable (left ventricle, 2.1 +/- 0.8 V; right ventricle, 1.1 +/- 0.4 V). Dobutamine therapy was no longer needed in 2 patients after they underwent biventricular pacing. No mortality or morbidity resulted from the procedure, and 2 patients were readmitted to the hospital, once each after the procedure over the 2-year follow-up period. The data show that the surgical approach for cardiac resynchronization therapy has durable long-term results.

Thoracoscopic talc pleurodesis for recurrent, symptomatic pleural effusion following cardiac operations.

Seventeen patients who underwent a cardiac operation developed a recurrent, symptomatic pleural effusion ultimately requiring video-assisted thoracic surgery (VATS) and talc pleurodesis. These patients represented 0.4% of all patients undergoing a cardiac operation over the same time period. Compared with an age- and sex-matched control group of cardiac surgery patients, patients requiring VATS for recurrent pleural effusion were more obese with higher body mass index (31.9 +/- 1.2 versus 28.3 +/- 1.4 kg/M2, P = 0.03), were more likely to have undergone a complex cardiac operation (8/17 versus 1/17, P =.01) and were more frequently on anticoagulation and antiplatelet agents besides aspirin (8/17 versus 2/17, P =.02). Patients underwent 1.86 +/- 0.34 thoracenteses with drainage of 846 +/- 166 mL/thoracentesis prior to referral for VATS. On average, patients underwent VATS 4.83 +/- 1.49 months after their cardiac operation. There were 3 VATS-related complications (17.6%) and no deaths. VATS talc pleurodesis led to symptomatic and radiologic improvement in all patients with a mean follow-up of 8.2 +/- 1.5 months. VATS talc pleurodesis effectively and safely treats the unusual postcardiac surgery patient with refractory pleural effusion.